Company Encyclopedia
View More
name
abrdn Life Sciences Investors
HQL.US
News
View More

When Will 3billion, Inc. (KOSDAQ:394800) Breakeven?

3billion, Inc. (KOSDAQ:394800) is nearing breakeven, with analysts predicting profitability by 2027. The company, specializing in rare disease drug discovery, reduced its losses from ₩6.6b to ₩6.0b. Analysts expect a 107% annual growth rate to achieve breakeven in two years. Notably, 3billion operates without debt, relying on shareholder funding, which reduces investment risk.

Simplywall·
US
RARE
-2.13%
Simplywall·
US
RARE
-2.13%

Expanded FDA Approvals and Pipeline Wins Could Be a Game Changer For Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals announced major milestones in November 2025, including FDA approvals for EYLEA HD in expanded indications and Libtayo as an adjuvant therapy for cutaneous squamous cell carcinoma. Positive late-stage trial results in hematology and immunology were also reported. These developments highlight Regeneron's expanding commercial portfolio and research pipeline. The FDA approval for EYLEA HD's new dosing and expanded indications is particularly significant, potentially counterbalancing competitive pressures. However, risks such as payer scrutiny and biosimilar erosion remain. Analysts have varied revenue and earnings forecasts for Regeneron.

Simplywall·
US
REGN
+5.01%
Simplywall·
US
REGN
+5.01%

VP Grygiel Files To Sell 3,139 Of Amgen Inc [AMGN]

Nancy A. Grygiel, Vice President of Amgen Inc, filed a Form 144 with the SEC on November 20, 2025, to sell 3,139 shares through Raymond James & Associates. The sale is permitted within 90 days of filing.

Reuters·
US
AMGN
-1.85%
Reuters·
US
AMGN
-1.85%

Amgen (AMGN) Gets a Hold from Mizuho Securities

Mizuho Securities maintained a Hold rating on Amgen with a $280 price target. Cantor Fitzgerald also issued a Hold rating, while Piper Sandler reiterated a Buy rating on Amgen.

Tip Ranks·
US
AMGN
-1.85%
Tip Ranks·
US
AMGN
-1.85%

Dir Bassler Files To Sell 760 Of Regeneron Pharmaceuticals Inc [REGN]

Bassler Bonnie L, Director of Regeneron Pharmaceuticals Inc, filed a Form 144 with the SEC to sell 760 shares through RBC Capital Markets, under a prearranged trading plan (10b5-1). The filing allows the sale within 90 days.

Reuters·
US
REGN
+5.01%
Reuters·
US
REGN
+5.01%